Roche’s Lucentis Works to Treat Vision Loss from Diabetes
This article is for subscribers only.
Roche Holding AG’s Lucentis works to treat a leading cause of blindness associated with diabetes, U.S. regulators said.
The injection improved vision in people with diabetic macular edema, Food and Drug Administration staff said in a report today ahead of a July 26 meeting of agency advisers on expanding approval of Lucentis. The drug is already used to treat wet age-related macular degeneration. Both diseases involve swelling of the macula, in the center of the retina.